

# PVRI 2024 Meeting Report

The next 50 years of Pulmonary Hypertension  
- a global view

London, 31 January - 4 February 2024





# A word from the CEO

Dear colleagues

I'd like to thank all those who attended PVRI 2024 London - our biggest meeting yet! It was my first PVRI Congress since joining the team in 2022, and what a high to start on. It was wonderful to finally put faces to so many names and meet our members and community from around the world.

From scientific talks and satellite meetings, to the Gala Dinners and a Women in PH Luncheon, it really was an excellent meeting and we've received some great feedback. We've put together this brief report as a snapshot of how it went, but if you have any questions, please do get in touch - we'd love to hear from you.

See you next year!

**Karen Osborn**

PVRI CEO



**524**

Delegates

**33**

Countries

**211**

Abstract posters accepted

**64**

Presentations in the main programme

**77**

Presentations in our pre- and post-meetings

**100%**

Panels had male and female representation

**49%**

Female delegates

**51%**

Male delegates

# 18

Pharmaceutical companies participated: MSD & Merck, United Therapeutics Coportation, Gossamer Bio, Keros Therapeutics, Chiesi Farmaceutici SpA, Liquida,, Aerovate Therapeutics, Fluida, Inc, Aerami Therapeutics, Inc, Thaerapy, Regeneron Pharmaceuticals Inc, Roivant Sciences Inc, Apollo Therapeutics LLP, Cereno Scientific, Tectonic Therapeutic, Deerfield, Ferrer, Morphic Therapeutic

## 97%

Of delegates rated the networking opportunities as excellent or good

## 94%

Of delegates rated the range and quality of education as excellent or good


## 97%

Of delegates rated the overall conference as excellent or good



# A global view

PVRI2024 London was attended by 542 people from 33 countries: Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Colombia, Denmark, Egypt, Ethiopia, France, Germany, Greece, India, Ireland, Italy, Japan, Mexico, Mozambique, Netherlands, New Zealand, Poland, Portugal, Romania, South Africa, Spain, Sweden, Switzerland, Turkey, United Kingdom, United States, and Zambia.



“Uniquely, PVRI meetings have more of a global scope and so there's a lot of opportunities for people from around the world, especially in lower and middle income countries to share research and to engage with the broader PH community here”

Jason Weatherald, University of Alberta



“The camaraderie and the collegiality that I feel at this meeting is really more than in any other meeting that I have visited”.

Zeenat Safdar,  
Houston Methodist Hospital

**76%**

Of delegates were at senior career (fully qualified) level

**24%**

Of delegates were early career (trainee) level



#PVRI2024

# Thank you to our sponsors & charity partners

## Premium Sponsor, MSD

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we've been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world's most challenging diseases.

## Women in PH Luncheon sponsor, United Therapeutics Corporation

Women are often absent from leadership positions in medicine and industry-driven activities. This presents opportunities to learn, diversify decision-making and innovate ideas to improve patient care. The time has come to change this paradigm. 'Women in PH' began as a way to support educational opportunities for women in PH and strengthen their professional network, aimed at building an inclusive, diverse community. We strive to unite and amplify women's voices to strengthen their collective interest.

## Silver sponsor, Thaerapy

Thaerapy Pharma was founded in 2023. The ae in Thaerapy stands for aerosol. Thaerapy is creating a PRN, Pro Re Nata, treatment for PAH patients. Thaerapy's TRP-001 program is repurposing an existing drug, Treprostinil, for immediate relief of symptoms and increased exercise capacity. Thaerapy uses a pocket size soft mist inhaler device, to enable the patient to take the treatment when needed. More information can be found at [thaerapy.com](http://thaerapy.com).

## Our charity partners, PHA UK, PHA USA & PHA Europe

Thank you to PHA UK, PHA USA and PHA Europe for their attendance and collaboration which plays a pivotal role in advancing our shared cause.



**See you  
next year**

**The Pulmonary Vascular Research Institute (PVRI) is a registered charity**  
(no. 1127115) and a company limited by guarantee (no. 05780068)